Invicro   Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2008)

Organization Overview

First Clinical Trial
2017
NCT03472313
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Invicro

Active Ingredients

Drugs in Phase 2 Trials (1)

apn-1607 (2 trials)

Drugs in Phase 1 Trials (9)

111in-dota-h11b6 (1 trial)

131 i-omburtamab (1 trial)

[18f]mni-444 (1 trial)

florbetapir (Amyvid) (1 trial)

mni-1054 (2 trials)

mni-1126 (1 trial)

mni-958 (2 trials)

pf-06412562 (1 trial)

ucb-2897 (1 trial)

Drugs in Other Trials (1)

cannabis (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Neoplasm Metastasis (Phase 1)

Parkinson Disease (Phase 1)

Prostatic Neoplasms (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Supranuclear Palsy, Progressive (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 11